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Edited by Varda RotterAbstract Recognition of phosphorylated serine/threonine-con-
taining motifs by 14-3-3 depends on the dimerization of 14-3-3.
However, the molecular cues that control 14-3-3 dimerization
are not well understood. In order to identify proteins that control
14-3-3 dimerization, we analyzed proteins that have eﬀects on
14-3-3 dimerization and report that protein kinase A (PKA)
phosphorylates 14-3-3f at a speciﬁc residue (Ser58). Phosphory-
lation by PKA leads to modulation of 14-3-3f dimerization and
aﬀect its interaction with partner proteins. Substitution of
Ser58 to Ala completely abolished phosphorylation of 14-3-3f
by PKA. A phospho-mimic mutant of 14-3-3f, Ser58 to Glu sub-
stitution, failed to form homodimers, showed reduced interaction
with 14-3-3e and p53, and could not enhance transcriptional
activity of p53. Moreover, activation of PKA decreases and inhi-
bition of PKA increases the dimerization of 14-3-3f and the func-
tional interaction of 14-3-3f with p53. Therefore, our results
suggest that PKA is a new member of protein kinases that can
phosphorylate and impair the function of 14-3-3.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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14-3-3 proteins are small acidic proteins with molecular mass
of 28–33 kDa and they usually exist as dimers. 14-3-3 proteins
are expressed ubiquitously in eukaryotes and their protein se-
quences are highly conserved from yeast to mammals [1–3]. Se-
ven isoforms in mammals, encoded by seven distinct genes,
more than 10 in plants, and two each in yeast, Drosophila,
and Caenorhabditis elegans have been identiﬁed [4]. 14-3-3 pro-
teins from various phyla are functionally conserved, such that
yeast homologs are functionally interchangeable with those of
plant and mammalian. The 14-3-3 family proteins preferen-
tially bind to phospho-serine/threonine-containing motifs
[5,6]. Structural analyses of 14-3-3, crystallized alone or in
complex with short synthetic peptides, revealed dimeric struc-*Corresponding authors. Fax: +82 62 530 2949 (K.-Y. Lee), +82 2
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tion and target binding: speciﬁc residues and regions in the
amino terminus are critical for dimerization and residues both
in the carboxy and amino termini are critical for target bind-
ings [7–9]. Mutational analysis of 14-3-3 proteins supported
these ﬁndings [10–12].
14-3-3 proteins regulate multiple signaling pathways in-
volved in the control of cell division, growth, and apoptosis
[1,13,14]. 14-3-3 binding to conserved peptide motifs of
RSXpSXP or RXXXpSXP is required for a range of context
dependent eﬀects, including alteration of enzymatic activity,
cellular localization, susceptibility to proteases and phospha-
tases, or the ability to incorporate into protein complexes [1].
For example, 14-3-3 binding is required for the stabilization
of active Raf-1 [15,16], Cdc25-mediated cell cycle control
[17,18], inhibition of proapoptotic Bad [19], and the function
of FoxO [20,21].
Functioning as phospho-Ser/Thr binding protein, 14-3-3 it-
self appears to be controlled by phosphorylation process
[22]. Dimerization and target binding are dependent on the
phosphorylation of 14-3-3 [23], and three phosphorylation
sites on 14-3-3f (Ser58, Ser184 and Thr232) have been identi-
ﬁed [1]. Phosphorylation of 14-3-3f at Ser184 residue increases
its interaction with PKC and this interaction downregulates
the enzymatic activity of PKC in vitro [24]. c-Jun NH2-termi-
nal kinase phosphorylated 14-3-3f at Ser184 both in vitro and
in vivo, and such phosphorylation reduced the aﬃnity of 14-3-
3 proteins for Bax and c-Abl [25,26]. In contrast, phosphoryla-
tion at Thr232 residue by Casein kinase I dissociates 14-3-3f
from Raf-1 in HEK293 cells [23]. Although sphingosine-
dependent protein kinase-1 (SDK1) and protein kinase B
(PKB/Akt) are known to phosphorylate the Ser58 residue of
14-3-3f, its signiﬁcance is not clearly understood [27,28].
Protein kinase A (PKA) plays a key role in the signaling of
many G protein-coupled receptors through the activation of
adenylate cyclase and production of cAMP. Phosphorylation
of nuclear and cytoplasmic substrates by PKA is critical for
multiple cell functions, including metabolism, diﬀerentiation,
synaptic transmission, ion-channel activity, growth and devel-
opment [29].
From amino acids sequence analysis of 14-3-3f, a potential
PKA phosphorylation site (RRXpSX) was identiﬁed at
Ser58. In the present study, we inquire whether PKA phosphor-
ylates 14-3-3f at Ser58 and regulates 14-3-3f homo- and hetero-
dimerization process. Given that 14-3-3f can interact with
numerous signaling proteins including p53 tumor suppressor,blished by Elsevier B.V. All rights reserved.
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by 14-3-3f phosphorylation. To test this, we examined the eﬀect
of a phospho-mimic mutation of 14-3-3f for the interaction
with p53 and the ability to enhance p53 transcriptional activity.
In contrast to wild type of 14-3-3f, the phospho-mimic form ap-
pears lose the aﬃnity for p53 and the ability to increase p53
transcriptional activity. In addition, we examined whether
modulation of PKA activity aﬀect the function of 14-3-3f using
speciﬁc chemical modulators of PKA activity. Activation of
PKA reduces 14-3-3f dimerization and its functional interac-
tion with p53. Inhibition of PKA has opposite eﬀects. In
conclusion, our results demonstrate that the PKA phosphory-
lates and controls the dimerization process of 14-3-3f resulting
in reduced interaction with and activation of p53.2. Materials and methods
2.1. Cell culture
All culture media and antibiotics were purchased from Invitrogen.
293 cells were maintained in DMEM supplemented with 10% fetal bo-
vine serum and antibiotics-antimycotics at 37 C, 5% CO2.
2.2. Plasmids and antibodies
Myc- or HA-tagged 14-3-3f, 14-3-3e and p53 were constructed in a
CMV promoter-derived mammalian expression vector (pCS4+). Anti-
bodies against 14-3-3 (Santa Cruz), Myc (9E10, Santa Cruz), HA
(12CA5, Roche), PKA (Santa Cruz) and tubulin (Sigma) were used.
2.3. DNA transfection and reporter assay
Transient transfections were performed using the calcium phosphate
and Lipofectamine plus methods. For luciferase assays, 293 cells were
plated on 24 well plates one day before transfection. pCMV b-gal plas-
mid was included as an internal control for transfection eﬃciency. At
12 h post-transfection, cells were treated with Forskolin or H89 (1000-
fold stocks in DMSO) for 24 h when necessary. For luciferase assay,
cells were lysed at 36 h post-transfection and the luciferase activity
was measured using Luciferase Reporter Assay Kit (Promega).Fig. 1. PKA phosphorylates 14-3-3f at Ser58 in vitro. (A) PKA
phosphorylates 14-3-3f. 293 cells are transfected with Myc-tagged 14-
3-3f, and anti-Myc immunoprecipitate is incubated with active2.4. Immunoprecipitation and immunoblotting
293 cells were lysed in ice-cold lysis buﬀer (25 mM HEPES [pH 7.5],
150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 10% glycerol,
25 mM NaF, 1 mM EDTA, 1 mM Na3VO4, 250 lM PMSF, 10 lg/ml
leupeptin and 10 lg/ml aprotinin) and cleared by centrifugation.
Supernatants were subjected to immunoprecipitation using appropri-
ate antibodies and protein A or protein G–Sepharose beads. Bound
proteins were resolved by SDS–PAGE and transferred to PVDF mem-
branes. Proteins were visualized using appropriate primary antibodies,
horseradish peroxidase-coupled secondary antibodies and chemilumi-
nescence Western blotting reagent (Amersham Bioscience).
2.5. In vitro kinase assay
Phosphorylation of 14-3-3f by PKA was examined by incubation of
active recombinant PKA with 5 lCi of [c-32P]ATP and anti-Myc
immunoprecipitate in 20 ll of kinase buﬀer (20 mM Tris–Cl (pH
7.4), 10 mM MgCl2, 50 lM ATP) in the presence or absence of a
PKA inhibitor peptide (PKI, 10 lM) for 20 min at 37 C. Reactions
were terminated with Laemmli SDS sample buﬀer. Half of each reac-
tion was used for evaluation of 14-3-3f phosphorylation by autoradi-
ography after SDS–PAGE (8% polyacrylamide) and the other half
was used for anti-PKA immunoblotting.recombinant PKA and [c-32P]ATP in the presence or absence of a
PKI (10 lM ﬁnal concentration). Amounts of Myc-tagged 14-3-3f and
PKA proteins in in vitro kinase reactions are also compared (IB: Myc
and IB: PKA). Note that PKA phosphorylates 14-3-3f and 14-3-3f
phosphorylation is inhibited in the presence of PKI. (B) PKA cannot
phosphorylate 14-3-3f (S58A). 293 cells are transfected with Myc-
tagged wild type 14-3-3f or 14-3-3f (S58A), and anti-Myc immuno-
precipitates are incubated with PKA and [c-32P]ATP.3. Results
3.1. PKA phosphorylates 14-3-3f in vitro
To determine if PKA is capable of phosphorylating 14-3-3f,
we performed an in vitro kinase assay. Active recombinantPKA was incubated with immunoprecipitated Myc-tagged
14-3-3f and [c-32P]ATP in the presence or absence of a PKI.
PKA phosphorylated 14-3-3f and this phosphorylation was
inhibited by PKI (Fig. 1A). A search of 14-3-3f amino acid se-
quence revealed a region (RRS58SW) similar to the consensus
PKA phosphorylation motif (RRXpSX). To determine if PKA
phosphorylates 14-3-3f at Ser58, a point mutant with Ser58 to
Alanine substitution, 14-3-3f (S58A), was generated. The abil-
ity of PKA to phosphorylate Myc-tagged 14-3-3f and 14-3-3f
(S58A) was determined by an in vitro kinase assay. PKA phos-
phorylated 14-3-3f but not 14-3-3f (S58A), suggesting that the
primary PKA phosphorylation site on 14-3-3f is Ser58.
3.2. Phosphorylation of 14-3-3f at Ser58 inhibits dimerization
Structural studies of 14-3-3f showed that Ser58 is located at
the dimer interface. To determine if phosphorylation at Ser58
modulates dimerization, dimerization of a phospho-mimic mu-
tant 14-3-3f (S58E) was compared to that of 14-3-3f and 14-3-
3f (S58A) by coimmunoprecipitation. Myc-tagged 14-3-3f
(S58E) or 14-3-3f (S58A) is cotransfected with HA-tagged
14-3-3f, 14-3-3f (S58E) or 14-3-3f (S58A) to 293 cells. The
binding of HA-tagged 14-3-3f proteins to Myc-tagged 14-3-
3f proteins is examined by anti-HA immunoblotting of anti-
Myc immunoprecipitates. 14-3-3f (S58E) did not bind to wild
type 14-3-3f or 14-3-3f (S58E) but weakly bound to 14-3-3f
(S58A) (Fig. 2A). However, 14-3-3f (S58A) bound strongly
to 14-3-3f (S58A) but very weakly, if at all, with 14-3-3f
(S58E) (Fig. 2B). These results suggest that wild type 14-3-3f
and 14-3-3f (S58A) form dimers, while 14-3-3f (S58E) does
not.
To determine the eﬀect of 14-3-3f phosphorylation on het-
erodimerization, interaction of Myc-tagged 14-3-3f proteins
with HA-tagged 14-3-3f or 14-3-3e was examined by coimmu-
noprecipitation. 14-3-3f (S58E) showed signiﬁcantly reduced
ability to heterodimerize with 14-3-3e compared to wild type
14-3-3f and 14-3-3f (S58A), while 14-3-3f (S58A) interacted
strongly with 14-3-3f and 14-3-3e (Fig. 3). These results sug-
gest that heterodimerization of 14-3-3f with 14-3-3e, as well
Fig. 2. Phosphorylation of 14-3-3f at Ser58 inhibits dimerization.
Myc-tagged 14-3-3f (S58E) or 14-3-3f (S58A) is cotransfected with
HA-tagged 14-3-3f, 14-3-3f (S58E) or 14-3-3f (S58A) in 293 cells.
Dimerization of Myc-tagged 14-3-3f (S58E) or 14-3-3f (S58A) with
HA-tagged 14-3-3f proteins is examined by anti-Myc immunoprecip-
itation followed by anti-HA immunoblotting (IP: Myc, IB: HA).
Arrows indicate the position of HA-tagged 14-3-3f proteins. Amounts
of Myc-tagged 14-3-3 proteins in anti-Myc immunoprecipitates (IP:
Myc, IB: Myc), and amounts of tubulin and epitope-tagged proteins in
total lysates are also compared (IB: Tubulin, IB: HA or IB: Myc). (A)
A phospho-mimic mutant 14-3-3f (S58E) shows reduced homodimer-
ization. (B) A PKA-mediated phosphorylation defective mutant 14-3-
3f (S58A) shows increased homodimerization.
Fig. 3. Phosphorylation of 14-3-3f at Ser58 inhibits heterodimeriza-
tion with 14-3-3e. Myc-tagged 14-3-3f, 14-3-3f (S58E) or 14-3-3f
(S58A) is cotransfected with HA-tagged 14-3-3f or 14-3-3e in 293 cells.
Dimerization of Myc-tagged 14-3-3f proteins with HA-tagged 14-3-3f
or 14-3-3e is examined by anti-Myc immunoprecipitation followed by
anti-HA immunoblotting (IP: Myc, IB: HA). Amounts of tubulin and
epitope-tagged proteins in total lysates are also compared (IB:
Tubulin, IB: HA or IB: Myc). Fig. 4. PKA inhibits 14-3-3f dimerization. Myc-tagged 14-3-3f and
HA-tagged 14-3-3f are cotransfected in 293 cells, and transfected cells
are treated with increasing amounts of a PKA activator Forskolin
(100 nM to 5 lM ﬁnal concentration) or a PKA inhibitor H89 (10 nM
to 1 lM ﬁnal concentration) or vehicle (DMSO) alone. Dimerization
of Myc-tagged 14-3-3f with HA-tagged 14-3-3f is examined by anti-
Myc immunoprecipitation followed by anti-HA immunoblotting (IP:
Myc, IB: HA). Amounts of Myc-tagged 14-3-3f in anti-Myc immu-
noprecipitates (IP: Myc, IB: Myc) and HA-tagged 14-3-3f in total
lysates are also compared (IB: HA).
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phorylation at Ser58 with Glu substitution.
3.3. PKA inhibits 14-3-3f dimerization
We then examined if PKA can regulate dimerization of 14-3-
3f. Transfected 293 cells were treated with a PKA activator(Forskolin) or a PKA inhibitor (H89), and the eﬀect of PKA
activation or inhibition on dimerization of 14-3-3f was exam-
ined by coimmunoprecipitation. Dimerization of 14-3-3f was
gradually decreased in the presence of increasing amounts of
Forskolin (Fig. 4), whereas the dimerization of 14-3-3f was
gradually increased in the presence of increasing amounts of
H89. These results indicate that PKA inhibits 14-3-3f dimer-
ization in vivo.
3.4. Phosphorylation of 14-3-3f Ser58 by PKA inhibits 14-3-3f
interaction with p53
14-3-3 isoforms (r, e, s and f) were found to interact with
p53 and p53 induces transcription of 14-3-3r, which in turn
positively regulates p53 [30,31]. To investigate the possible role
of Ser58 phosphorylation by PKA on the interaction of 14-3-
3f with p53, interaction of wild type 14-3-3f or 14-3-3f (S58E)
with p53 was examined by coimmunoprecipitation. 14-3-3f
(S58E) showed signiﬁcantly decreased interaction with p53
compared to wild type 14-3-3f (Fig. 5A). These results suggest
that phosphorylation at Ser58 may also regulate 14-3-3f inter-
action with p53.
We then examined if PKA can regulate the interaction of 14-
3-3f with p53. HA-tagged p53 was cotransfected with wild type
or mutant 14-3-3f, and transfected cells were treated with For-
skolin or H89. The eﬀect of PKA activation or inhibition on
the interaction between 14-3-3f and p53 was examined. The
binding of p53 to wild type 14-3-3f or 14-3-3f mutants was in-
creased when PKA was inhibited by H89 compared to their
binding when PKA was activated by Forskolin or in the ab-
sence of any chemical modulator (Fig. 5B). These results sug-
gest that PKA may inhibit the interaction between 14-3-3f and
p53.
3.5. PKA regulates 14-3-3f-enhanced transcriptional activity of
p53
14-3-3r enhances the transcriptional activity of p53. We
examined the eﬀect of 14-3-3f, 14-3-3f (S58E) or 14-3-3f
(S58A), and the eﬀect of PKA activation or inhibition on the
transcriptional activity of p53 using a p53-responsive luciferase
reporter, p21 2300-luc. p21 2300-luc contains p53 response ele-
ments of p21 CDKN1A promoter. p21 2300-luc and p53 were
Fig. 5. Phosphorylation of 14-3-3f at Ser58 by PKA inhibits 14-3-3f interaction with p53. (A) 14-3-3f (S58E) show reduced ability to interact with
p53. HA-tagged p53 is cotransfected with Myc-tagged 14-3-3f or 14-3-3f (S58E) in 293 cells. Interaction between 14-3-3f proteins and p53 is
determined by anti-Myc immunoprecipitation followed by anti-HA immunoblotting (IP: Myc, IB: HA). Amounts of tubulin and epitope-tagged
proteins in total lysates are also compared (IB: Tubulin, IB: HA or IB: Myc). (B) PKA inhibits 14-3-3f interaction with p53. Myc-tagged 14-3-3f and
HA-tagged p53 are cotransfected in 293 cells. Transfected cells are treated with a PKA activator Forskolin (For), a PKA inhibitor H89 (H89) or
DMSO alone (V). Interaction between 14-3-3f proteins and p53 is determined by anti-Myc immunoprecipitation followed by anti-HA
immunoblotting (IP: Myc, IB: HA). Amounts of Myc-tagged 14-3-3f in anti-Myc immunoprecipitates (IP: Myc, IB: Myc) and HA-tagged p53 in
total lysates (IB: HA) are also compared.
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293 cells. Transfected cells were treated with H89 or DMSO
alone, and the transcriptional activity of p53 was determined
by luciferase assay. Wild type 14-3-3f and 14-3-3f (S58A) en-
hanced the transcriptional activity of p53 while 14-3-3f
(S58E) did not (Fig. 6). These results suggest that phosphory-
lation of 14-3-3f at Ser58 may control the ability of 14-3-3f to
enhance the transcriptional activity of p53. The wild type 14-3-
3f-enhanced p53 transcriptional activity was further increased
by inhibiting PKA with H89. These results suggest that PKA0
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Fig. 6. 14-3-3f and inhibition of PKA enhance the transcriptional
activity of p53. p21-2300-luc, a p53-responsive luciferase reporter, is
cotransfected with indicated combinations of p53, 14-3-3f, 14-3-3f
(S58E) and 14-3-3f (S58A) in 293 cells. Transfected cells are treated
with a PKA inhibitor (H89, ﬁlled bars) or vehicle alone (DMSO,
empty bars). Numbers indicate the amount of DNA used for
transfection in lg. Relative luciferase activities with S.D. are shown.inhibits the ability of 14-3-3f to enhance the transcriptional
activity of p53. Interestingly, H89 also increased p53 transcrip-
tional activity in cells where p53 was cotransfected with 14-3-
3f (S58E) or 14-3-3f (S58A). This increase may occur because
inhibition of PKA facilitates dimerization of 14-3-3f mutants
with endogenous 14-3-3f, as the dimerization of 14-3-3f
(S58E) or 14-3-3f (S58A) with wild type 14-3-3f was increased
by H89, and/or because inhibition of PKA facilitate the dimer-
ization of 14-3-3f with 14-3-3e or other 14-3-3 isoforms, as
14-3-3f can dimerize with 14-3-3e and their interaction is also
aﬀected when Ser58 of 14-3-3f is mutated.4. Discussion
14-3-3 plays essential roles in intracellular signaling by inter-
acting with and regulating the activity of a battery of cell sig-
naling components; including G protein-coupled IL receptors,
regulators of G protein signaling proteins, protein kinases
(Raf-1, protein kinase C, Akt, PI3K, ASK1, and MEKK1),
protein phosphatases (IP5P and PTPH1), and transcription
factors (FKHRL1 and GR) [32]. By recognizing and binding
to short phosphorylated peptide motifs, 14-3-3f controls cell
proliferation, apoptosis, vesicle transport, cytoskeletal organi-
zation, and gene expression. Intriguingly though, phosphoryla-
tion of 14-3-3f itself appears to be a critical regulatory
mechanism controlling the function of 14-3-3f; Aitken et al. re-
ported that phosphorylation at Ser184 of 14-3-3f increases
interaction with PKC and inhibits PKC activity in vitro [24].
Casein kinase I phosphorylates Thr232, interfering 14-3-3f
interaction with Raf-1 in HEK293 cells [23]. SDK1 and
PKB/Akt phosphorylates Ser58, but the eﬀect of this phos-
phorylation on 14-3-3f function is not clear [27,28]. Here, we
analyzed whether PKA phosphorylates 14-3-3f and regulates
the function of 14-3-3f.
The present study demonstrates that PKA phosphorylates
14-3-3f at Ser58. Substitution of Ser58 to Ala completely abol-
Y.-M. Gu et al. / FEBS Letters 580 (2006) 305–310 309ishes PKA-mediated phosphorylation of 14-3-3f, suggesting
that Ser58 is the primary phosphorylation site of 14-3-3f by
PKA. Ser58 is located at the 14-3-3 dimer interface [11], and
this implies that phosphorylation may aﬀect 14-3-3 dimeriza-
tion [8]. We demonstrate that a phospho-mimic mutant 14-3-
3f (S58E) loses its ability for homo- and hetero-dimerization
compared to wild type. Conversely, a PKA-mediated phos-
phorylation defective mutant 14-3-3f (S58A) shows increased
ability for homo- and heterodimerization compared to wild
type. In addition, we demonstrate that activation of PKA re-
duces 14-3-3f dimerization while inhibition of PKA increases
14-3-3f dimerization.
We also demonstrate that PKA-mediated phosphorylation
of 14-3-3f at Ser58 inhibits the functional interaction of 14-
3-3f with p53. 14-3-3f (S58E) mutant shows signiﬁcantly re-
duced ability to bind p53, and inhibition of PKA increases
14-3-3f binding to p53. 14-3-3f and 14-3-3f (S58A) enhance
the transcriptional activity of p53 whereas 14-3-3f (S58E) can-
not. In addition, inhibition of PKA further increases 14-3-3f-
enhanced p53 transcriptional activity. Taken together, our
results suggest that the phosphorylation of 14-3-3f at Ser58
by PKA can regulate 14-3-3f dimerization and its interaction
with binding partners.
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